Small Molecules Targeting Biological Clock; A Novel Prospective for Anti-Cancer Drugs

被引:17
作者
Rahman, Sadia [1 ]
Wittine, Karlo [1 ]
Sedic, Mirela [1 ]
Markova-Car, Elitza P. [1 ]
机构
[1] Univ Rijeka, Dept Biotechnol, Rijeka 51000, Croatia
来源
MOLECULES | 2020年 / 25卷 / 21期
关键词
circadian rhythm; biological clock; cancer; small molecules; anticancer drugs; PROTEIN-KINASE CK2; REV-ERB-ALPHA; CIRCADIAN GENE-EXPRESSION; LIVER X RECEPTORS; BREAST-CANCER; CELL-CYCLE; TUMOR-GROWTH; INHIBITION; AUTOPHAGY; SENSITIVITY;
D O I
10.3390/molecules25214937
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The circadian rhythms are an intrinsic timekeeping system that regulates numerous physiological, biochemical, and behavioral processes at intervals of approximately 24 h. By regulating such processes, the circadian rhythm allows organisms to anticipate and adapt to continuously changing environmental conditions. A growing body of evidence shows that disruptions to the circadian rhythm can lead to various disorders, including cancer. Recently, crucial knowledge has arisen regarding the essential features that underlie the overt circadian rhythm and its influence on physiological outputs. This knowledge suggests that specific small molecules can be utilized to control the circadian rhythm. It has been discovered that these small molecules can regulate circadian-clock-related disorders such as metabolic, cardiovascular, inflammatory, as well as cancer. This review examines the potential use of small molecules for developing new drugs, with emphasis placed on recent progress that has been made regarding the identification of small-molecule clock modulators and their potential use in treating cancer.
引用
收藏
页数:20
相关论文
共 132 条
[1]  
Antoch Marina P, 2013, Handb Exp Pharmacol, P289, DOI 10.1007/978-3-642-25950-0_12
[2]   Clock genes in mammalian peripheral tissues [J].
Balsalobre, A .
CELL AND TISSUE RESEARCH, 2002, 309 (01) :193-199
[3]   Circadian dysfunction in disease [J].
Bechtold, David A. ;
Gibbs, Julie E. ;
Loudon, Andrew S. I. .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2010, 31 (05) :191-198
[4]   Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A [J].
Burgermeister, Elke ;
Battaglin, Francesca ;
Eladly, Fagr ;
Wu, Wen ;
Herweck, Frank ;
Schulte, Nadine ;
Betge, Johannes ;
Haertel, Nicolai ;
Kather, Jakob N. ;
Weis, Cleo-Aron ;
Gaiser, Timo ;
Marx, Alexander ;
Weiss, Christel ;
Hofheinz, Ralf ;
Miller, Ian S. ;
Loupakis, Fotios ;
Lenz, Heinz-Josef ;
Byrne, Annette T. ;
Ebert, Matthias P. .
EBIOMEDICINE, 2019, 45 :139-154
[5]   Loss of circadian clock gene expression is associated with tumor progression in breast cancer [J].
Cadenas, Cristina ;
van de Sandt, Leonie ;
Edlund, Karolina ;
Lohr, Miriam ;
Hellwig, Birte ;
Marchan, Rosemarie ;
Schmidt, Marcus ;
Rahnenfuehrer, Joerg ;
Oster, Henrik ;
Hengstler, Jan G. .
CELL CYCLE, 2014, 13 (20) :3282-3291
[6]   A Role for the Clock Gene Per1 in Prostate Cancer [J].
Cao, Qi ;
Gery, Sigal ;
Dashti, Azadeh ;
Yin, Dong ;
Zhou, Yan ;
Gu, Jiang ;
Koeffler, H. Phiflip .
CANCER RESEARCH, 2009, 69 (19) :7619-7625
[7]  
Carew Jennifer S, 2012, Cancer Manag Res, V4, P357, DOI 10.2147/CMAR.S26133
[8]   Antiobesity Effect of a Small Molecule Repressor of RORγ [J].
Chang, Mi Ra ;
He, Yuanjun ;
Khan, Tanya M. ;
Kuruvilla, Dana S. ;
Garcia-Ordonez, Ruben ;
Corzo, Cesar A. ;
Unger, Thaddeus J. ;
White, David W. ;
Khan, Susan ;
Lin, Li ;
Cameron, Michael D. ;
Kamenecka, Theodore M. ;
Griffin, Patrick R. .
MOLECULAR PHARMACOLOGY, 2015, 88 (01) :48-56
[9]   The gluttonous side of malignant melanoma: basic and clinical implications of macroautophagy [J].
Checinska, Agnieszka ;
Soengas, Maria S. .
PIGMENT CELL & MELANOMA RESEARCH, 2011, 24 (06) :1116-1132
[10]   Per2 participates in AKT-mediated drug resistance in A549/DDP lung adenocarcinoma cells [J].
Chen, Bo ;
Tan, Yaoxi ;
Liang, Yan ;
Li, Yan ;
Chen, Lei ;
Wu, Shuangshuang ;
Xu, Wei ;
Wang, Yan ;
Zhao, Weihong ;
Wu, Jianqing .
ONCOLOGY LETTERS, 2017, 13 (01) :423-428